Thirty years into the HIV/AIDS epidemic, and more than a decade into antiretroviral treatment (ART) being introduced in developing countries, the latest scientific evidence shows that treatment both keeps people healthy, and prevents the virus from spreading to others. Alongside these findings come several new treatment approaches, including providing ART earlier in people's disease progression.
Twelve years after having started providing ART in developing countries, Médecins Sans Frontières (MSF) now has more than 222,000 people on treatment in its projects in 23 countries. In several of its projects, the medical organisation has started to introduce some of these new approaches.
Micaela Serafini, Medical Referent for Médecins Sans Frontières, speaks about MSF’s work in Swaziland, providing earlier treatment to pregnant women living with HIV, expanding testing and treatment in the community, and implementing improved technology to monitor how patients’ treatment is working.
Q: Why is it important to provide antiretroviral treatment to people living with HIV while their immune system is still strong?
Today, we measure the level of an HIV-positive person’s white blood cells to determine when to start them on treatment, because this is an indicator of how strong their immune system is. Right now, the World Health Organization recommends starting people on ART when their CD4 cell count drops to 350 cells per mm3 of blood, but asks countries to consider earlier ART for pregnant women and HIV positive partners in couples where one person is HIV-positive and the other is not, called ‘sero-discordant’ couples. A healthy person’s CD4 count ranges from 800 to 1,200—the lower the count, the more prone a person is to becoming ill from opportunistic infections like tuberculosis.
Raising the CD4 count threshold for initiation of treatment from CD4 350 to CD4 500 would be a positive step, since more people would be provided treatment, and we know that starting treatment early keeps patients healthy. We also now know that treatment itself limits transmission of the virus, as proven by a scientific breakthrough last year. Treatment is a critical part of the prevention toolbox.
In Swaziland, MSF is studying the feasibility and acceptance of the ‘Test and Treat’ (T&T) model, the most radical option of Treatment as Prevention (TasP). It involves providing all HIV-positive people with treatment, regardless of their CD4 count. This approach would allow us to have a maximum impact on reducing illness, as well as transmission of HIV in the community.
We are currently paving the way for TasP in Swaziland with the implementation of a greatly improved treatment protocol for pregnant women in order to better prevent mother-to-child transmission of HIV, or PMTCT, and help keep the mother healthy. The protocol is referred to as ‘Option B+’. In a nutshell, PMTCT Option B+ is Test and Treat for pregnant women: we aim to start all HIV-positive pregnant women on life-long treatment, regardless of their CD4 count.
In Swaziland, HIV prevalence among pregnant women is extremely worrying, reaching as high as 40%! The added-value of Option B+ is four-fold: it keeps the mother healthy, it prevents the baby from contracting HIV, it prevents the transmission from mother to child during future pregnancies and it also protects the mother’s partner if he is HIV negative.
This new pilot project is just starting in the south of the country, in the Shiselweni region, which has a population of 208,000 people. We hope to start PMTCT B+ this month and from there put on ARV treatment 3,000 pregnant women every year. In 2013, we will expand this approach to other vulnerable groups and eventually to all HIV-positive adults in the region.
Q: Have people in the community generally been willing to get tested for HIV?
Well, this is where it sometimes gets complicated. We talk a lot about new science and theoretical models show us that if all goes according to plan, we could have future generations totally free of HIV. This is extremely stimulating for the scientific and medical community!
So while pregnant women in Swaziland are indeed going to health centres to get tested, we see the main difficulty remains in testing the men in the community. So, we need to change the way we look at things, and the way we do them, as well. Since men are reluctant to go to health centres, we need to bring the option of being tested to them. In Swaziland, MSF has implemented a community-based testing activity where typically a community worker can do the counselling and testing and refer the person to the health centre if the test is positive. We try to bring the care as close as possible to the people and to adapt our way of working according to the population we want to help. We take into consideration cultural aspects, which help us understand why, for example, a lot of men in Swaziland don’t want to get tested for HIV.
Q: Another important aspect of HIV care is making sure people’s treatment is working, through regular monitoring. What is ‘viral load,’ and why is MSF using it?
Antiretroviral treatment stops the virus from multiplying, so measuring a person’s ‘viral load’—the number of copies of the HIV virus in a given blood sample—is important in order to see how people are doing on treatment. When the virus is well suppressed and treatment is working at its best, a person is considered to have ‘undetectable’ viral load. In this case, it makes it less likely that the person will transmit the virus.
While we measure a person’s CD4 cell level to check the state of the immune system and determine when a person should start treatment, viral load testing shows us whether the virus is still replicating, which is a sign that a person may be having trouble adhering to their treatment. We know from experience that once identified through viral load monitoring, a person with adherence problems benefits from targeted counselling to help get them back on track. Viral load monitoring can also help detect whether the virus may have developed resistance to the drugs they are taking and they may need to be switched to other medicines immediately.
CD4 takes much longer to show how people are doing on their treatment, because there is a delay with the immune system reacting to the virus. This means we’re not getting people on track until months or even years later, which is not ideal for their health. Testing viral load is like sending an SMS text message, while testing CD4 amounts to sending a letter through the mail.
In Swaziland, we are currently studying the best way to decentralise the use of viral load monitoring to simplify and improve the patients’ follow-up. When you spot treatment failure or poor adherence early, it is less likely people will develop resistance to the drugs and also the patient’s health is less likely to deteriorate. By decentralising viral load monitoring, instead of having to travel all the way to the district hospital, the patient can get the test done in his or her local health centre. This is what we hope to achieve with the mini-labs we set up in remote clinics and health centers. The clinics are now equipped with everything needed to do HIV tests, CD4 counts, pregnancy tests and biochemistry. Viral load will be added to this package.
Measuring viral load has another important role to play—it tells us right away whether a newborn of a mother with HIV has been infected or not. This helps us anticipate potential problems and tailor a baby’s treatment. It’s called ‘early infant diagnosis.’ With the current rapid diagnostic test, children can only be tested to see if they are HIV-positive six months after they stop breast-feeding, because otherwise it is impossible to determine whether the HIV antibodies found in their blood are from the mother or the infant. At present, the risk of death in children with HIV is high, because the tools available don’t allow for them to be diagnosed at birth and therefore start treatment earlier. Thankfully, viral load can change this, but it needs to be scaled up.